WO2021020509A1 - 間葉系幹細胞の増殖促進または減少抑制のための組成物 - Google Patents

間葉系幹細胞の増殖促進または減少抑制のための組成物 Download PDF

Info

Publication number
WO2021020509A1
WO2021020509A1 PCT/JP2020/029229 JP2020029229W WO2021020509A1 WO 2021020509 A1 WO2021020509 A1 WO 2021020509A1 JP 2020029229 W JP2020029229 W JP 2020029229W WO 2021020509 A1 WO2021020509 A1 WO 2021020509A1
Authority
WO
WIPO (PCT)
Prior art keywords
serpin
mesenchymal stem
acid sequence
amino acid
stem cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2020/029229
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
克人 玉井
敬史 新保
尊彦 山崎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
StemRIM Inc
University of Osaka NUC
Original Assignee
Osaka University NUC
StemRIM Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osaka University NUC, StemRIM Inc filed Critical Osaka University NUC
Priority to JP2021535424A priority Critical patent/JP7561348B2/ja
Priority to US17/631,072 priority patent/US20220265787A1/en
Publication of WO2021020509A1 publication Critical patent/WO2021020509A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/73—Hydrolases (EC 3.)
    • C12N2501/734—Proteases (EC 3.4.)

Definitions

  • mesenchymal stem cells particularly mesenchymal stem cells of bone marrow.
  • a therapeutic effect on inflammatory bowel disease can be expected.
  • FIG. 3 shows the results of a colony assay showing changes in colony-forming cells in the bone marrow of DSS-treated mice.
  • the number of colonies (%) of DSS-administered mice on the same collection day is shown when the average value of the number of colonies formed from the bone marrow cells of healthy mice on each collection day is taken as 100%.
  • FIG. 4 shows the results of a colony assay when bone marrow cells of DSS-administered mice were cultured in a serpin A3N-added medium.
  • the bone marrow includes, but is not limited to, the bone marrow of the femur, tibia, skull, sternum, vertebrae, ribs, and pelvic bone.
  • serpin A3 or a composition comprising it promotes or suppresses the proliferation of bone marrow mesenchymal stem cells (ie, mesenchymal stem cells contained within the bone marrow cells). In a further embodiment, serpin A3 or a composition comprising it promotes or suppresses the proliferation of bone marrow colony forming mesenchymal stem cells.
  • Serpin A3 or a composition containing it is administered to a subject in an amount capable of exerting a desired effect (referred to as "effective amount" in the present specification).
  • the dose is appropriately determined depending on the age, weight, health condition, etc. of the subject.
  • the dose can be selected in the range of 0.000000001 mg to 1000 mg per 1 kg of body weight per administration.
  • the dose can be selected in the range of 0.00001 to 100,000 mg / body per subject.
  • Serpin A3 for use in promoting or suppressing the proliferation of mesenchymal stem cells.
  • Serpin A3 for use in the treatment of inflammatory bowel disease.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PCT/JP2020/029229 2019-07-31 2020-07-30 間葉系幹細胞の増殖促進または減少抑制のための組成物 Ceased WO2021020509A1 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021535424A JP7561348B2 (ja) 2019-07-31 2020-07-30 間葉系幹細胞の増殖促進または減少抑制のための組成物
US17/631,072 US20220265787A1 (en) 2019-07-31 2020-07-30 Composition for promoting growth or suppressing decrease of mesenchymal stem cells

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2019141325 2019-07-31
JP2019-141325 2019-07-31
JP2020-058544 2020-03-27
JP2020058544 2020-03-27

Publications (1)

Publication Number Publication Date
WO2021020509A1 true WO2021020509A1 (ja) 2021-02-04

Family

ID=74230673

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2020/029229 Ceased WO2021020509A1 (ja) 2019-07-31 2020-07-30 間葉系幹細胞の増殖促進または減少抑制のための組成物

Country Status (3)

Country Link
US (1) US20220265787A1 (https=)
JP (1) JP7561348B2 (https=)
WO (1) WO2021020509A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3556378B1 (en) 2017-01-27 2025-03-12 StemRIM Inc. Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure
US20210024594A1 (en) 2018-02-08 2021-01-28 StemRIM Inc. Therapeutic Agent for Psoriasis

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03181422A (ja) * 1989-12-04 1991-08-07 John Lezdey 炎症の治療方法及び炎症の治療用合成薬
JPH09512423A (ja) * 1994-03-31 1997-12-16 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルベニア エラスターゼ阻害活性を有するα−１−アンチキモトリプシンアナログ
WO2008053892A1 (en) * 2006-10-30 2008-05-08 Genomix Co., Ltd. Pharmaceutical for promoting functional regeneration of damaged tissue
WO2009133939A1 (ja) * 2008-04-30 2009-11-05 株式会社ジェノミックス 末梢循環への骨髄由来多能性幹細胞動員薬
JP2018502579A (ja) * 2015-01-08 2018-02-01 アプセト ゲーエムベーハー アンド ツェーオー．カーゲー α１−アンチトリプシン（ＡＡＴ）を発現する遺伝子改変された間葉系幹細胞

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03181422A (ja) * 1989-12-04 1991-08-07 John Lezdey 炎症の治療方法及び炎症の治療用合成薬
JPH09512423A (ja) * 1994-03-31 1997-12-16 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルベニア エラスターゼ阻害活性を有するα−１−アンチキモトリプシンアナログ
WO2008053892A1 (en) * 2006-10-30 2008-05-08 Genomix Co., Ltd. Pharmaceutical for promoting functional regeneration of damaged tissue
WO2009133939A1 (ja) * 2008-04-30 2009-11-05 株式会社ジェノミックス 末梢循環への骨髄由来多能性幹細胞動員薬
JP2018502579A (ja) * 2015-01-08 2018-02-01 アプセト ゲーエムベーハー アンド ツェーオー．カーゲー α１−アンチトリプシン（ＡＡＴ）を発現する遺伝子改変された間葉系幹細胞

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ORIMA, ICHIRO: "The Evaluation of the Human Neutrophil Elastase in Inflammatory Bowel Disease", JOURNAL OF THE KYORIN MEDICAL SOCIETY, vol. 25, no. 4, 1994, pages 537 - 544, XP055789732 *

Also Published As

Publication number Publication date
JPWO2021020509A1 (https=) 2021-02-04
US20220265787A1 (en) 2022-08-25
JP7561348B2 (ja) 2024-10-04

Similar Documents

Publication Publication Date Title
US20240050460A1 (en) Pharmaceuticals That Promote Functional Regeneration of Damaged Tissues
JP5960735B2 (ja) 損傷組織の機能的再生促進医薬
JP6199936B2 (ja) 骨髄間葉系および／または多能性幹細胞の血中動員による組織再生促進剤
CN113194978B (zh) 具有间充质干细胞的动员活性的肽
US20240368235A1 (en) Disease Treatment Drug Based on Mesenchymal-Stem-Cell Mobilization
KR20150102957A (ko) Hmgb1 단편을 이용한 척수 손상에 대한 신규 치료법
JP7561348B2 (ja) 間葉系幹細胞の増殖促進または減少抑制のための組成物
JP7672636B2 (ja) 間葉系幹細胞の動員活性を有するペプチド
Devine Tumor Induced Cardiovascular Dysfunction
HK1156211A (en) Pharmaceutical agent for promoting the functional regeneration of damaged tissue
JPH0987199A (ja) 腎糸球体疾患治療剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20847533

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2021535424

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20847533

Country of ref document: EP

Kind code of ref document: A1